|- candidate number||28191|
|- NTR Number||NTR6829|
|- ISRCTN||ISRCTN no longer applicable|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||13-nov-2017|
|- Secondary IDs||2016_336 |
|- Public Title||CFTR microbiome analysis |
|- Scientific Title||Changes in the respiratory microbial and biochemical environment after the start of CFTR targeted treatment in patients with cystic fibrosis|
|- hypothesis||1) After the initiation of targeted CFTR therapy: |
a. Microbiome diversity increases (primary hypothesis, also used for sample size calculation)
b. Well-adapted microbial species (e.g. Pseudomonas, Achromobacter) decrease in abundance
c. The biochemical environment moves towards normal (e.g. increased pH)
2) An improved lung function is associated with:
a. Increased diversity of the microbiome
b. Decreased abundance of well-adapted microbial species (e.g. Pseudomonas)
c. Increased pH and less inflammatory response
3) Patients with a microbiome that is less well-adapted to the CF lung environment tend to show less clinical improvement.
|- Healt Condition(s) or Problem(s) studied||Cystic Fibrosis (CF)|
|- Inclusion criteria||In order to be eligible to participate in this study, a subject must meet all of the following criteria:|
Patients with a (predominant) class II mutation (almost exclusively homozygous Phe508del) for cystic fibrosis.
Start with Ivacaftor/Lumacaftor (Orkambi) therapy
|- Exclusion criteria||A potential subject who meets any of the following criteria will be excluded from participation in this study:|
For bronchoscopy the following patients will be excluded:
Pre-lung transplant trajectory
No informed consent for the procedure
Deemed inappropriate by the treating physician.
|- mec approval received||yes|
|- multicenter trial||no|
|- Type||Single arm|
|- planned startdate ||13-nov-2017|
|- planned closingdate||1-mei-2019|
|- Target number of participants||20|
|- Interventions||Start of orkambi is part of routine care. |
|- Primary outcome|| Bacterial sequences in sputum, broncho-alveolar lavage fluid and oral and nasal wash. |
Metabolic profiles in broncho-alveolar lavage fluid and oral wash.
Volatile metabolites in breath.
|- Secondary outcome|| Bacterial culture result from sputum and broncho-alveolar lavage fluid. |
Long function test results (FEV1/FVC, etc).
Plasma parameters of (chronic) inflammation: IgG, CRP, leukocyte count.
Quality of life assessments.
|- Timepoints||Before start. After 3,6,9 and 12 months. |
|- Trial web site|
|- status||open: patient inclusion|
|- CONTACT FOR PUBLIC QUERIES|| Lieuwe D.J. Bos|
|- CONTACT for SCIENTIFIC QUERIES|| Lieuwe D.J. Bos|
|- Sponsor/Initiator ||University of Amsterdam (UvA)|
(Source(s) of Monetary or Material Support)
|Longfonds The Netherlands |
|- Brief summary||Rationale: The lungs of patients with CF are characterized by (1) impaired mucus clearance, (2) acidic milieu, (3) increased number of neutrophils and (4) increased bacterial loads. Novel therapies target the CF transport receptor (CFTR) and increase its activity. They improve lung function in patients with a specific mutation. However, very little is known about the influence of the targeted CFTR therapies on the respiratory microbiome. One of the major challenges in CF is to limit the colonization of the respiratory tract by well-adapted microbes such as Pseudomonas and Achromobacter and maintain a healthy respiratory flora. |
Objective: We aim to evaluate the changes in the composition and the function of the respiratory microbiome after the initiation of targeted CFTR therapy. Second we want to relate the change in respiratory biochemical and microbial environment to clinical changes (for example lung function). Finally, we will explore the differences in pre-medication respiratory microbiome / metabolome between patients that clinically respond and do not respond to treatment.
Study design: Longitudinal observational cohort study.
Study population: Patients with a (predominant) class II mutation (almost exclusively homozygous Phe508del) for cystic fibrosis (N=20) who will be started on Ivacaftor/Lumacaftor (CFTR targeted therapy; Orkambi) therapy will be included in this longitudinal observational study. There are no exclusion criteria.
Main study parameters/endpoints: Five visits are planned per patient as part of standard care. Material will obtained during all visits. Lung function, microbial cultures of sputum and blood sampling will be performed as part of routine care. An oral wash, nasal wash and exhaled breath will be obtained as additional procedure. A bronchoscopic bronchial wash of the central airways and both lungs will be performed in patients that (1) have no contra-indications for bronchoscopy and (2) provide informed consent for this procedure. During bronchoscopy, breath will be obtained from both lungs separately through the bronchoscope. Functional metagenomic and metabolomics analysis will be performed on sputum samples, broncho-alveolar lavage fluid and oral and nasal wash. The primary endpoint is the change in bacterial diversity after the start of Ivacaftor/Lumacaftor.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: All assessment will be performed in conjunction with routine visits to the outpatient clinic as much as possible. The most important additional procedure for the patient are two additional bronchoscopies in a selected group of patients. This procedure is unpleasant but is of low risk in the patients that are included for bronchoscopy. The patient will not have benefit from participation in the study. We aim for improved treatment of bacterial dysbalance in the respiratory tract of all patients with CF and in that respect the results of the study may improve treatment in the future for the patients participating in the study or any patient with similar characteristics.
|- Main changes (audit trail)|
|- RECORD||13-nov-2017 - 7-dec-2017|